Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Pharma Economics – 101

By Pharmaceutical Processing | July 30, 2014

There has always been much hand-wringing and shouting regarding the costs of new medications. Most of this comes from people outside the industry – politicians, public health advocates, and a smattering of those that just like to hear themselves talk.

I was reminded of this recently when a story crossed my desk that Gilead’s hepatitis C treatment, Sovaldi was being sold for $1,000 a pill and even at that price it had become the treatment of choice for hepatitis c sufferers. Apparently the prospect of a cure with fewer side effects had driven the number of prescriptions way up – and subsequently brought out the congressmen, insurance industry reps and Medicaid reps demanding answers as to why the treatment cost so much – and digging their heals in regarding payment.

Well, I’ll tell you why it costs so much. Developing a drug costs a ton of money. It also takes a long time. The company that develops the drug undertakes a huge financial risk and technical challenge to bring a product to market – with absolutely no guarantees. A company that succeeds in getting a drug to market should be able to price it at what the market will bear and what they think will allow them a return on investment to continue research into other products.

Also, regarding the $1,000 a pill price tag – I have my reservations that that is the actual price paid by consumers. As anyone who has filled a prescription and is lucky enough to have health care coverage knows, there is the “retail” price and then there is the insurance company’s “negotiated” price, which is usually far less. Unfortunately those that don’t have insurance because they can’t afford it are also forced to pay full price for the medical bills and to have their prescriptions filled. A “double-whammy” if you will.

Would this conundrum be solved if there was some sort of universal healthcare plan? Maybe you should ask your congressional representative

Related Articles Read More >

The blueprint for personalized biopharma
Sai Life Sciences opens dedicated veterinary-API unit alongside flagship Bidar site
This is the logo of Johnson & Johnson.
Johnson & Johnson commits $2B investment to North Carolina manufacturing facility
Bionova The Woodlands Texas pDNA facility (1)
Bionova opens new plasmid DNA materials production plant in Texas
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE